IFNB1 antibody (N-Term)
Quick Overview for IFNB1 antibody (N-Term) (ABIN453696)
Target
See all IFNB1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- N-Term
-
Specificity
- This antibody reacts to IFNB1.
-
Purification
- Affinity chromatography on Protein A
-
Immunogen
- KLH conjugated synthetic peptide selected from the N-terminal region of human Interferon beta 1/IFNB1.
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Western blotting: 1/100 - 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS containing 0.09 % (W/V) sodium azide as preservative
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))
-
Alternative Name
- IFNB / Interferon beta
-
Background
- The mammalian type I Inteferons (IFN1) are produced in response to viral infection and other inducers. They are divided into alpha and beta subtypes leukocytes and fibroblasts reactivity. The human IFN alphas are encoded by a family of at least 15 different genes, while IFN beta is the unique member of its subtype. There is approximately 50 % amino acid homology between the alpha and beta subtypes. Both IFN subtypes are pleiotropic cytokines and have a similar range of biological activities. Differences between alpha subtypes, and between IFN alpha and betas, are in potency and cell type specific activities. In particular, IFN beta elicits a markedly higher antiproliferation response in some cell types such as, embryonal carcinoma, melanoma and melanocytes than do IFN alphas. Higher potency of IFN beta in treatment of multiple sclerosis and certain cancers has been observed. Type I IFNs signal through binding to a common cell surface receptor. Two chains of the receptor, IFNAR1 and IFNAR2, have been identified. Both chains are necessary for function and in the absence of either there is neither high affinity binding nor biological activity. The intracellular portions of the receptor subunits are bound by tyrosine kinases, Jak1 and Tyk2, members of the Janus kinase family. Upon ligand binding these kinases are activated and phosphorylate members of the STAT family of transcription factors, as well as IFNAR1 and 2. IFNB1 has antiviral, antibacterial and anticancer activities.Synonyms: Fibroblast interferon, IFB, IFN-beta, IFNB1
-
Gene ID
- 3456
-
NCBI Accession
- NP_002167
-
UniProt
- P01574
-
Pathways
- JAK-STAT Signaling, TCR Signaling, TLR Signaling, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Autophagy, Inflammasome
Target
-